182 related articles for article (PubMed ID: 17952556)
1. A possible method using baseline hormonal levels to prescribe the appropriate oral therapeutic radioiodine dosage for Graves' disease.
Nakajo M; Tsuchimochi S; Jinguji M; Tanabe H; Umanodan T; Nakabeppu Y
Ann Nucl Med; 2007 Oct; 21(8):471-6. PubMed ID: 17952556
[TBL] [Abstract][Full Text] [Related]
2. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
3. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
Howarth D; Epstein M; Lan L; Tan P; Booker J
Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
[TBL] [Abstract][Full Text] [Related]
4. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism.
Siegmund W; Spieker K; Weike AI; Giessmann T; Modess C; Dabers T; Kirsch G; Sänger E; Engel G; Hamm AO; Nauck M; Meng W
Clin Endocrinol (Oxf); 2004 Jun; 60(6):750-7. PubMed ID: 15163340
[TBL] [Abstract][Full Text] [Related]
5. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
6. The value of estimating serum aproptotic marker concentrations in monitoring and prognosis of 131I--therapy in Graves' disease. Preliminary report.
Rogowski F; Parfieńczyk A; Sopotyk A; Budlewski T; Jabłońska E; Kiersnowska-Rogowska B; Szumowski P
Nucl Med Rev Cent East Eur; 2004; 7(2):117-22. PubMed ID: 15968597
[TBL] [Abstract][Full Text] [Related]
7. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease?
Schneider P; Körber C; Körber-Hafner N; Hänscheid H; Reiners C
Nuklearmedizin; 2002 Dec; 41(6):240-4. PubMed ID: 12520660
[TBL] [Abstract][Full Text] [Related]
8. Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy.
Nakajo M; Tsuchimochi S; Tanabe H; Nakabeppu Y; Jinguji M
Ann Nucl Med; 2005 Jun; 19(4):297-308. PubMed ID: 16097639
[TBL] [Abstract][Full Text] [Related]
9. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
10. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
11. Early treatment with low fixed dose (5 mCi) radioiodine therapy is effective in Indian subjects with Graves' disease.
Sanyal D; Mukhhopadhyay P; Pandit K; Chatterjee J; Raychaudhuri M; Mukherjee S; Chowdhury S
J Indian Med Assoc; 2008 Jun; 106(6):360-1, 372. PubMed ID: 18839646
[TBL] [Abstract][Full Text] [Related]
12. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
Gómez Arnaiz N; Gómez Saez JM; Orti Llavería A; Gavaldá Mestre L; Mairal Pairó L; Soler Ramón J
Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
[TBL] [Abstract][Full Text] [Related]
13. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
El Refaei SM; Shawkat W
Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
[TBL] [Abstract][Full Text] [Related]
14. What influences early hypothyroidism after radioiodine treatment for Graves' hyperthyroidism?
Vijayakumar V; Ali S; Nishino T; Nusynowitz M
Clin Nucl Med; 2006 Nov; 31(11):688-9. PubMed ID: 17053385
[TBL] [Abstract][Full Text] [Related]
15. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
Traino AC; Grosso M; Mariani G
Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
[TBL] [Abstract][Full Text] [Related]
17. Predictor of outcome of hyperthyroidism due to Graves disease: serum triiodothyronine/thyroxine ratio.
Khanna CM; Shankar LR; Jaggi CB; Bansal JK; Chugh P
J Assoc Physicians India; 1996 Feb; 44(2):98-101. PubMed ID: 10999059
[TBL] [Abstract][Full Text] [Related]
18. [Experience with ambulatory radioiodine therapy of hyperthyroidism].
Róka R; Séra T; Valkusz Z; Julesz J; Csernay L; Pávics L
Orv Hetil; 1999 Jun; 140(23):1291-5. PubMed ID: 10412264
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of radioiodine 131I treatment in Graves' disease patients with mild orbitopathy].
Bałdys-Waligórska A; Stefańska A; Gołkowski F; Sokołowski G; Hubalewska-Dydejczyk A
Przegl Lek; 2009; 66(4):166-9. PubMed ID: 19708504
[TBL] [Abstract][Full Text] [Related]
20. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study.
Vos XG; Smit N; Endert E; Tijssen JG; Wiersinga WM
Clin Endocrinol (Oxf); 2008 Aug; 69(2):311-7. PubMed ID: 18208575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
